Vita Life Sciences Limited
Appendix 4D
For the half year ended 30 June 2013

To :	Company Announcements		
Company:	Australian Securities Exchange	Fax No.:	
Date:	26 August 2013	No. of pages	24 incl. cover
From:	Ernest Chunge	Fax No.:	
Subject :	**Appendix 4D**		

Please see attached 30 June 2013 Half Yearly Report for Vita Life Sciences Limited (ASX - VSC).

This announcement is made pursuant to Listing rule 4.2A.3. For all enquiries please contact

Mr Ernest Chunge
Company Secretary
Vita Life Sciences Limited

Telephone 02 9545 2633

Fax 02 9545 1311

1. Company details

Name of entity

VITA LIFE SCIENCES LIMITED

ABN or equivalent company reference	Half year ended ('current period')	Half year ended ('previous period')
35 003 190 421	30 June 2013	30 June 2012

The information contained in this report is to be read in conjunction with Vita Life Sciences Limited's 2012 Annual Report and any announcements to the market by Vita Life Sciences Limited during the half year ended 30 June 2013.

2. Results for announcement to the market

			Percentage Change %	2013 A$'000
2.1	**Revenue**	up	18.5	17,083
	Profit before income tax	up	130.9	2,538
2.2	**Net profit after tax**	up	117.6	2,146
2.3	**Net profit attributable to members**	up	115.1	2,136

2.4	**Dividends (distributions)**			**Amount per security**	**Franked amount per security**
2.5	Interim 2013 dividend	Record Date To Be Paid	22 September 2013 29 September 2013	1.0 cents	0.41 cents
	Final 2012 dividend	Record Date Paid	15 March 2013 28 March 2013	0.5 cents	0.5 cents

2.6 Brief explanation of any of the figures in 2.1 to 2.4 above necessary to enable the figures to be understood.

The Board of Directors is pleased to announce Vita Life Sciences Limited's ("Group") revenue was $17.083m (2012: $14.407m) with an EBIT margin of 14.9% (2012: 7.7%) resulting in a profit after tax of $2.146m for the half year to 30 June 2013 (2012: $0.986m).

Revenue was driven by the continued growth from the Established Business Units in Australia, Malaysia and Singapore, with total sales of $14.758m (2012: $12.768m), an increase of 15.6%. Due to economies of scale resulting from the higher sales recorded, EBIT margins increased across the 3 countries when measured against the six months to June 2012.

The Group's New Business Units (Thailand, China, Malaysia MLM, Thailand, Vietnam and Indonesia) continued to show promising signs with revenue increasing by 41.9% to $2.325m (2012: $1.639m).

The Group's divisional result for 1st Half 2013 is summarised in the table below:

Half year ended 30 June	**2013**			**2012**		
	Health $'000	**Investment $'000**	**Total $'000**	**Health $'000**	**Investment $'000**	**Total $'000**
Revenue						
Sales to external customers	17,083	-	17,083	14,407	-	14,407
Total segment revenue	17,083	-	17,083	14,407	-	14,407
Result						
Segment results	2,763	(10)	2,753	1,396	(4)	1,392
Unallocated expenses			(163)			(221)
Profit before tax and finance costs			2,590			1,171
Finance costs			(52)			(72)
Profit before income tax			2,538			1,099
Income tax expense			(392)			(113)
Net profit for the year			2,146			986

3. Net tangible assets

	30 June 2013	30 June 2012
Net Tangible Assets per security	$0.26	$0.18

4. Entities over which control has been gained or lost during the period

Control over entities

Name of entity (or group of entities)	Not applicable

Loss of control over entities

Name of entity (or group of entities)	Not applicable

5. Dividends

A dividend of 0.5 cents per share fully franked amounting to $274,000 was paid on 28 March 2013 in relation to the year ended 31 December 2012.

Directors have declared the payment of an interim dividend for the year ending 31 December 2013 of 1.0 cent per ordinary share franked to 41%, as disclosed at point 2.4 above.

6. Dividend Reinvestment plans

The Board of Directors have resolved to suspend the Company's DRP until further notice.

7. Details of associates and joint venture entities

	Place of Incorporation	Ownership Interest 30 June 2013 %	Ownership Interest 30 June 2012 %
Investment details			
Name of Company			
Unlisted			
- Mitre Focus Sdn Bhd	Malaysia	6.3	6.3

8. Information on Audit or Review

This interim report is based on accounts to which one of the following applies

The accounts have been subject to review	☑
The accounts are in the process of being subject to review	☐
The accounts have not yet been reviewed	☐

Description of likely dispute or qualification if the accounts have not yet been audited or subject to review or are in the process of being audited or subjected to review.

Not applicable

9. For foreign entities, which accounting standards were used in compiling this report.

International Financial Reporting Standard - IFRS

Vita Life Sciences Limited

Half Year Report 30 June 2013

Vita Life Sciences Limited and its Controlled Entities
ABN 35 003 190 421

Contents

Directors' Report	1
Auditor's Independence Declaration	2
Condensed Consolidated Statement of Comprehensive Income	3
Condensed Consolidated Statement of Financial Position	4
Condensed Consolidated Statement of Cash Flow	5
Condensed Consolidated Statement of Changes in Equity	6
Notes to the Condensed Consolidated Financial Statements	8
Directors' Declaration	14
Independent Review Report	15
General Information	17

.

Directors' Report

The Directors of Vita Life Sciences Limited ("Company" or "Vita Life") submit their report together with the financial report for Vita Life and its controlled entities for the half year ended 30 June 2013.

DIRECTORS

The names of the Company's directors in office throughout and since the end of the last financial period are set out below.

Mr Vanda R Gould	Non-executive chairman
Mr Eddie L S Tie	Managing director
Mr Henry G Townsing	Non-executive director
Mr Jonathan J Tooth	Non-executive director

All directors have been in office since the start of the financial year to the date of this report unless otherwise stated.

PRINCIPAL ACTIVITIES

During the period in review the principal continuing activities of the consolidated entity consisted of formulating, packaging, sales and distribution of vitamins and supplements and investment.

OPERATING AND FINANCIAL REVIEW

Operating Results for the Half Year

For the reporting period the consolidated entity recorded a consolidated profit after tax attributable to members of $2,136,000 (2012: $993,000).

ROUNDING OFF

The Company is if a kind referred to in ASIC Class Order 98/100 dated 10 July 1998 and in accordance with that Class Order, amounts in the financial report and Directors' report have been rounded off to the nearest thousand dollars, unless otherwise stated.

AUDITOR'S INDEPENDENCE DECLARATION

The Directors have received an Independence Declaration from the external auditor, Russell Bedford NSW. A copy of this Declaration follows the Directors Report.

Signed in accordance with a resolution of the Board of Directors made pursuant to s.306(3) of the Corporations Act 2001.

Eddie L S Tie
Managing Director
Sydney, 26 August 2013

Auditor's Independence Declaration

Russell Bedford
New South Wales

Level 42, Suncorp Place
259 George Street
Sydney NSW 2000
Australia

T: **+61 2 9032 3050**
F: +61 2 9032 3058
E: **mail@russellbedfordnsw.com.au**
W: www.russellbedford.com.au

26 August 2013

The Board of Directors
Vita Life Sciences Limited
Suite 650, Level 6
1 Queens Road. St Kilda Towers
MELBOURNE VIC 3004

LEAD AUDITOR'S INDEPENDENCE DECLARATION UNDER SECTION 307C OF THE CORPORATIONS ACT 2001

As lead auditor for the review of the financial statements of Vita Life Sciences Limited for the half year ended 30 June, 2013, I declare that, to the best of my knowledge and belief, there has been no contravention of:

- the auditor independence requirements as set out in the Corporations Act 2001 in relation to the review; and
- contraventions of any applicable code of professional conduct in relation to the review.

RUSSELL BEDFORD NSW
Chartered Accountants

Gregory C. Ralph, M.Com. FCA
Partner

Condensed Consolidated Statement of Comprehensive Income

For the half year ended 30 June 2013

	Notes	2013 $'000	2012 $'000
CONTINUING OPERATIONS			
Sale of goods		17,083	14,407
Cost of sales		(5,621)	(5,238)
Gross profit		11,462	9,169
Other income		44	38
Distribution expenses		(1,461)	(1,256)
Marketing expenses		(1,014)	(1,080)
Occupancy expenses		(380)	(360)
Administrative expenses		(5,911)	(5,315)
Other expenses		(191)	(84)
Share of associates (loss) / profit		(7)	-
Profit from continuing operations before interest and taxes		2,542	1,112
Finance income		48	59
Finance costs		(52)	(72)
Profit before income tax		2,538	1,099
Income tax expense		(392)	(113)
Net profit for the period		2,146	986
Other comprehensive income after income tax			
Exchange differences on translating foreign controlled entities		762	(166)
Other comprehensive income for the period, net of income tax		762	(166)
Total comprehensive income for the period		**2,908**	**820**
Profit attributable to minority interest		10	(7)
Profit attributable to members of the parent		2,136	993
		2,146	986
Total comprehensive income / (expense) attributable to:			
Minority interest		17	(9)
Members of the parent		2,891	829
		2,908	820
Earnings per share (cents per share)			
- basic earnings per share	5	3.88	1.83
- diluted earnings per share	5	3.79	1.72

The Condensed Consolidated Statement of Comprehensive Income should be read in conjunction with the accompanying notes to the Half Year Report.

Condensed Consolidated Statement of Financial Position

As at 30 June 2013

	Notes	30 June 2013 $'000	31 December 2012 $'000
ASSETS			
Current Assets			
Cash and cash equivalents		7,599	5,017
Trade and other receivables		4,764	4,481
Inventories		6,306	5,612
Other assets		421	469
Total Current Assets		19,090	15,579
Non Current Assets			
Investment in associates		1,044	947
Property, plant and equipment		253	126
Intangible assets		86	73
Deferred tax assets		120	88
Total Non Current Assets		1,503	1,234
Total Assets		**20,593**	**16,813**
LIABILITIES			
Current Liabilities			
Trade and other payables		5,162	4,591
Current tax liability		547	289
Provisions		563	542
Total Current Liabilities		6,272	5,422
Non Current Liabilities			
Deferred Tax Liability		9	8
Provisions		35	41
Total Non Current Liabilities		44	49
Total Liabilities		**6,316**	**5,471**
Net Assets		**14,277**	**11,342**
EQUITY			
Issued capital	6	46,257	45,956
Accumulated losses		(31,670)	(33,532)
Employee share based payments reserve		472	472
Foreign currency translation reserve		(885)	(1,640)
Parent entity interest		14,174	11,256
Minority interest		103	86
Total Equity		**14,277**	**11,342**

The Condensed Consolidated Statement of Financial Position should be read in conjunction with the accompanying notes to the Half Year Report.

Condensed Consolidated Statement of Cash Flow

For the half year ended 30 June 2013

	Notes	2013 $'000	2012 $'000
CASH FLOWS FROM OPERATING ACTIVITIES			
Receipt from customers		18,723	15,034
Payments to suppliers and employees		(16,012)	(13,996)
Borrowing costs		(52)	(44)
Income tax paid		(169)	(130)
Interest received		48	59
Net cash flows provided by operating activities		2,538	923
CASH FLOWS FROM INVESTING ACTIVITIES			
Proceeds from sale of property, plant and equipment		-	22
Purchase of property, plant and equipment		(183)	(56)
Cash received upon acquisition of subsidiary		-	181
Net cash flows (used in)/provided by investing activities		(183)	147
CASH FLOWS FROM FINANCING ACTIVITIES			
Dividends Paid		(274)	(272)
Proceeds from loan repayment from LTIP		407	411
Shares bought back (net of costs)		(106)	(100)
Proceeds from issue of shares		-	31
Net cash flows provided by financing activities		27	70
Net increase in cash and cash equivalents		2,382	1,140
Net foreign exchange differences		200	32
Cash and cash equivalents at beginning of the period		5,017	3,632
Cash and cash equivalents at end of the period		**7,599**	**4,804**

The Condensed Consolidated Statement of Cash Flow should be read in conjunction with the accompanying notes to the Half Year Report.

Condensed Consolidated Statement of Changes in Equity

for the half year ended 30 June 2013

	Note	Issued Capital $'000	Employee Share Based Payments Reserve $'000	Accumulated Losses $'000	Foreign Currency Translation Reserve $'000	Attributable to Equity Holders of Parent $'000	Minority Interests $'000	Total $'000
Balance at 1 January 2013		45,956	472	(33,532)	(1,640)	11,256	86	11,342
Comprehensive income								
Profit for the period		-	-	2,136	-	2,136	10	2,146
Other comprehensive income for the year		-	-	-	755	755	7	762
Total comprehensive income for the period		-	-	2,136	755	2,891	17	2,908
Transactions with owners, in their capacity as owners								
Shares bought back		(106)	-	-	-	(106)	-	(106)
Repayment of loans on Employee share option scheme		407	-	-	-	407	-	407
Dividends paid	7	-	-	(274)	-	(274)	-	(274)
Total transactions with owners		301	-	(274)	-	27	-	27
Balance at 30 June 2013		46,257	472	(31,670)	(885)	14,174	103	14,277

The Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the accompanying notes to the Half Year Report.

Condensed Consolidated Statement of Changes in Equity

for the half year ended 30 June 2013 (Cont.)

	Note	Issued Capital $'000	Employee Share Based Payments Reserve $'000	Accumulated Losses $'000	Foreign Currency Translation Reserve $'000	Attributable to Equity Holders of Parent $'000	Minority Interests $'000	Total $'000
Balance at 1 January 2012		45,568	272	(35,355)	(1,993)	8,492	464	8,956
Comprehensive income								
Profit attributable to members of parent entity		-	-	993	-	993	(7)	986
Other comprehensive income for the period		-	-	-	(164)	(164)	(2)	(166)
Total comprehensive income for the period		-	-	993	(164)	829	(9)	820
Transactions with owners, in their capacity as owners								
Issue of Shares (net of issue costs)		31	-	-	-	31	-	31
Recognition of non-controlling interest		-	-	-	-	-	87	87
Shares bought back		(100)	-	-	-	(100)	-	(100)
Repayment of loans on Employee share option scheme		411	-	-	-	411	-	411
Employee share option scheme		-	137	-	-	137	-	137
Dividends paid		-	-	(272)	-	(272)	-	(272)
Total transactions with owners		342	137	(272)	-	207	87	294
Balance at 30 June 2012		45,910	409	(34,634)	(2,157)	9,528	542	10,070

The Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the accompanying notes to the Half Year Report.

Notes to the Condensed Consolidated Financial Statements

for the half year ended 30 June 2013

1. CORPORATE INFORMATION

The Half Year financial report of Vita Life Sciences Limited ("Vita Life") and its controlled entities ("the Group") for the half year ended 30 June 2013 was authorised for issue by a resolution of the directors on the date of this report.

Vita Life is a Company limited by shares incorporated and domiciled in Australia whose shares are publicly traded on the Australian Securities Exchange ("ASX").

The nature of the operations and principal activities of the Group are described in the Director's Report.

2. BASIS OF PREPARATION

These general-purpose condensed consolidated financial statements for the half-year reporting period ended 30 June 2013, have been prepared in accordance with the requirements of the *Corporations Act 2001*, and Australian Accounting Standard AASB 134 "Interim Financial Reporting." The Group is a for-profit entity for financial reporting purposes under Australian Accounting Standards.

This interim financial report is intended to provide users with an update on the latest annual financial statements of Vita Life Sciences Limited. As such, it does not contain information that represents relatively insignificant changes occurring during the half-year within the Group. It is therefore recommended that this financial report be read in conjunction with the annual financial statements of the Group for the year ended 31 December 2012, together with any public announcements made during the following half-year.

The same accounting policies and methods of computation have been followed in this interim financial report as were applied in the most recent annual financial statements.

The half-yearly condensed consolidated financial statements have been prepared on a historical cost basis.

For the half-year reporting period to 30 June 2013, a number of new and revised Accounting Standard requirements became mandatory for the first time, and several were applicable to the Group. None of these have affect the Group's accounting policies or the amounts reported in the financial statements.

A short description of the new and amending Standards that became applicable to the Group for the first time during this half-year reporting period are as follows:

- *AASB 10 Consolidated financial statements:*

AASB 10 provides a revised definition of control and additional guidance so that a single control model will apply to all investees. Revised AASB 127 facilitates the application of AASB 10: the assets, liabilities and non-controlling interests related to investments in businesses that are now assessed as being controlled by the Group, and were therefore not previously consolidated, are measured as if the investee had been consolidated (and therefore applied acquisition accounting in accordance with AASB 3: Business Combinations) from the date when the Group obtained control of the investee on the basis of the requirements in AASB 10. This change did not affect the Group's accounting policies or the amounts reported in the financial statements.

Notes to the Condensed Consolidated Financial Statements (continued)

2. BASIS OF PREPARATION (CONT.)

- AASB 13: *Fair Value Measurement* and AASB 2011-8: *Amendments to Australian Accounting Standards arising from AASB 13.*

These Standards are mandatorily applicable from 1 January 2013 and thus, become applicable to the Group for the first time in the current half-year reporting period. AASB 13 sets out a comprehensive framework for measuring the fair value of assets and liabilities and prescribes enhanced disclosures regarding all assets and liabilities measured at fair value. These Standards did not affect the Group's accounting policies or the amounts reported in the financial statements.

- AASB 2012-2: *Amendments to Australian Accounting Standards – Disclosures – Offsetting Financial Assets and Financial Liabilities* and AASB 2012-5: *Amendments to Australian Accounting Standards arising from Annual Improvements 2009-2011 Cycle.*

These Standards make changes to presentation and disclosure requirements, but did not affect the Group's accounting policies or the amounts reported in the financial statements.

3. SEGMENT REPORTING

	Australia $'000	Singapore $'000	Malaysia $'000	Others $'000	Total $'000
Half year ended 30 June 2013					
Revenue					
Sales to external customers	6,925	2,741	5,945	1,472	17,083
Segment results					
Profit / (loss) before tax and finance costs	804	967	997	(171)	2,597
Finance costs	(24)	(1)	(25)	(2)	(52)
Share of profit of associates				(7)	(7)
Profit before income tax					2,538
Income tax expense					(392)
Net profit for the period					2,146
Assets and liabilities					
Segment assets	7,745	2,770	6,590	2,444	19,549
Investment in associates					1,044
Total assets					20,593
Segment liabilities	2,626	851	2,680	159	6,316
Total liabilities					6,316
Other segment information					
Capital expenditure	(7)	(61)	(89)	(26)	(183)
Depreciation	(3)	(17)	(13)	(4)	(37)
Amortisation	-	(5)	(1)	(1)	(7)

Notes to the Condensed Consolidated Financial Statements (continued)

3. SEGMENT REPORTING (CONT.)

	Australia $	Singapore $	Malaysia $	Others $	Total $
Half year ended 30 June 2012					
Revenue					
Sales to external customers	6,629	2,118	4,814	846	14,407
Segment results					
Profit / (loss) before tax and finance costs	705	377	536	(447)	1,171
Finance costs	(44)	(1)	(25)	(2)	(72)
Share of profit of associates	-	-	1	(1)	-
Profit before income tax					1,099
Income tax expense					(113)
Net profit for the period					986
Assets and liabilities					
Segment assets	7,388	1,632	3,878	1,653	14,551
Investment in associates					929
Unallocated assets					
Total assets					15,480
Segment liabilities	2,773	899	1,611	127	5,410
Total liabilities					5,410
Other segment information					
Capital expenditure	(7)	(10)	(17)	(22)	(56)
Depreciation	(2)	(14)	(19)	(8)	(43)
Amortisation	-	(4)	(1)	(1)	(6)

Notes to the Condensed Consolidated Financial Statements (continued)

4. NET TANGIBLE ASSETS

	30 June 2013 $	31 Dec 2012 $
Net assets per share	0.26	0.20
Net tangible assets per share	0.26	0.20
	Number	**Number**
Weighted average number of ordinary shares for net assets per share	55,013,690	56,474,638

5. EARNINGS PER SHARE

	30 June 2013 $'000	30 June 2012 $'000
(a) Earnings used in calculating earnings per share		
Net profit attributable to equity holders from continuing operations	2,146	986
(Profit) / Loss attributable to minority interest	(10)	7
Net profit attributable to equity holders of the parent used to calculate EPS	**2,136**	**993**
	Number	**Number**
(b) Weighted average number of shares		
Weighted average number of ordinary shares for basic earnings per share	55,013,690	54,184,724
Adjusted weighted average number of ordinary shares for diluted earnings per share	56,426,190	57,788,474

Notes to the Condensed Consolidated Financial Statements (continued)

6. CONTRIBUTED EQUITY

	30 June 2013 Number	30 June 2012 Number	30 June 2013 $	30 June 2012 $
Issued and paid up capital				
Ordinary shares	**56,369,295**	**57,653,508**	**46,256,952**	**45,909,529**
Ordinary shares				
Balance at beginning of the financial period	56,474,638	57,845,060	45,956,146	45,568,037
Share buy back (a)	(105,343)	(294,931)	(105,994)	(99,659)
Shares issued during the financial period	-	103,379		30,551
Cancellation of Plan Shares of certain employees and Director	-	(325,000)	-	-
Issue of shares to employee / director		325,000	-	-
Plan shares exercised (b)	-	-	406,800	410,600
Balance at end of the financial period	**56,369,295**	**57,653,508**	**46,256,952**	**45,909,529**

a) A total of 105,343 ordinary shares were bought back in the period ended 30 June 2013 as approved by the shareholders in the 16 May 2012 and 23 May 2013 Annual General Meetings at a total cost of $105,994.

b) During the period ended 30 June 2013, a sum of $406,800 was paid by the Managing Director and employees of the Group to retire limited recourse loans for a total of 1,695,000 ordinary shares issued under the Company's Long Term Incentive Plan in 2011.

7. DIVIDEND

A dividend of 0.5 cents per share fully franked amounting to $274,000 (2012: 0.5 cents per share fully franked totalling $272,000) was paid on 28 March 2013 in relation to the year ended 31 December 2012.

An interim dividend of 1.0 cents per share franked to 41% has been declared and will be paid on 29 September 2013. The record date for the interim dividend is 22 September 2013.

8. COMMITMENTS

There are no significant changes to the commitments as previously disclosed in the Annual Report for the financial year ended 31 December 2012.

9. EVENTS AFTER THE BALANCE SHEET DATE

Other than those mentioned in the financial statements and notes thereto, no matters or circumstances have arisen since the end of the financial period which significantly affected or could significantly affect the operations of the economic entity, the results of those operations or the state of affairs of the economic entity in future financial years.

10. CONTINGENT ASSETS AND LIABILITIES

The Group has no contingent assets or liabilities as at 30 June 2013.

Notes to the Condensed Consolidated Financial Statements (continued)

11. RELATED PARTIES DISCLOSURES

Transactions with related parties

The following table provides the total amount of transactions that were entered into with related parties for the relevant financial period.

	CONSOLIDATED	
	30 June 2013	30 June 2012
	$	$
Other transactions with related parties		
Business Intelligence & Support Inc. (i)	292,140	233,846
CVC Venture Managers Pty Ltd (ii)	50,091	55,102
Pilmora Pty Ltd (iii)	7,500	7,500
Melbourne Corporation Pty Ltd (iv)	15,975	-
	365,706	**296,448**

(i) Business Intelligence & Support Inc., a company in which Mr Eddie Tie is a director, and therefore a related party, provided international business advisory, sales, marketing and promotion services to the Group. $51,894 remained payable as at 30 June 2013, and is disclosed in trade and other payables.

(ii) CVC Venture Managers Pty Limited, a company in which Mr Vanda Gould and Mr Henry Townsing are directors, was paid consultancy fees during the financial period. There was no amount payable as at 30 June 2013.

(iii) Pilmora Pty Ltd, a company in which Mr Henry Townsing is a director was paid a consultancy fee during the financial period. There was no amount payable as at 30 June 2013.

(iv) Melbourne Corporation Pty Ltd, a company in which Mr Vanda Gould is a director, provided company secretarial services to the Group for which it was paid a fee during the financial period. There was no amount payable as at 30 June 2013.

Directors' Declaration

In the opinion of the directors of Vita Life Sciences Limited:

1. (a) The financial statements and notes of the consolidated entity are in accordance with the *Corporations Act 2001*, including:

   (i) giving a true and fair view of the consolidated entity's financial position as at 30 June 2013 and its performance for the half-year ended on that date; and

   (ii) complying with Accounting Standard AASB 134 *Interim Financial Reporting*, Corporations Regulations 2001 and other mandatory professional reporting requirements.

   (b) There are reasonable grounds to believe that the consolidated entity will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of the directors made pursuant to s.303(5) of the Corporations Act 2001:

Eddie L S Tie
Managing Director
Sydney, 26 August 2013

Independent Review Report

Russell Bedford
New South Wales

Level 42, Suncorp Place
259 George Street
Sydney NSW 2000
Australia

T: **+61 2 9032 3050**
F: +61 2 9032 3058
E: mail@russellbedfordnsw.com.au
W: www.russellbedford.com.au

Independent Review Report To the members of Vita Life Sciences Limited

Report on the Half-Year Financial Report

We have reviewed the accompanying half-year financial report of Vita Life Sciences Limited and the entities it controlled during the period which comprises the condensed consolidated statement of financial position as at 30 June 2013, the condensed consolidated statement of comprehensive income, condensed consolidated statement of changes in equity, condensed consolidated statement of cash flows for the half-year ended on that date, notes comprising a summary of significant accounting policies and other explanatory information, and the directors' declaration.

Directors Responsibility on the Half-Year Financial Report

The directors of Vita Life Sciences Limited are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards (including Australian Accounting Interpretations) and the Corporations Act 2001 and for such control as the directors determine is necessary to enable the preparation of the half-year financial report that is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express a conclusion on the half-year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410: Review of an Interim Financial Report Performed by the Independent Auditor of the Entity, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the financial report is not in accordance with the Corporations Act 2001 including: giving a true and fair view of the company's financial position as at 30 June 2013 and its performance for the half-year ended on that date; and complying with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Regulations 2001. As auditor of Vita Life Sciences Limited, ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. Our review did not involve an analysis of the prudence of business decisions made by directors or management.

Matters Relating to Electronic Publication of the Reviewed Financial Report

This review report relates to the financial report of Vita Life Sciences Limited for the half year period ended 30 June 2013 included on the website of Vita Life Sciences Limited. The directors of the company are responsible for the integrity of the website and we have not been engaged to report on this integrity. This review report refers only to the subject matter described above. It does not provide an opinion on any other information which may have been hyperlinked to or from the financial report. If users of the financial report are concerned with the inherent risk arising from publication on a website, they are advised to refer to the hard copy of the reviewed financial report to confirm the information contained in this website version of the financial report.

Independence

In conducting our review, we have complied with the independence requirements of the Corporations Act 2001.

Conclusion

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of Vita Life Sciences Limited and the entities it controlled during the period is not in accordance with the Corporations Act 2001 including:

a) giving a true and fair view of the consolidated entities financial position as at 30 June 2013 and of its performance for the half-year ended on that date; and

b) complying with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Regulations 2001.

RUSSELL BEDFORD NSW
Chartered Accountants

Gregory C. Ralph M.Com. FCA
Partner

Sydney, 26 August 2013

General Information

Board of Directors

Vanda Gould
Non-Executive Chairman

Eddie L S Tie
Managing Director

Jonathan Tooth
Non-Executive Director

Henry Townsing
Non-Executive Director

Company Secretary
Ernest Chunge

Corporate Office
Suite 650, Level 6
1 Queens Road
Melbourne VIC 3004
T: 61 (03) 9828 0500
F: 61 (03) 9820 5957

Australian Regional Office
Unit 1/ 102, Bath Road
Kirrawee
NSW 2232
T: 61 (02) 9545 2633
F: 61 (02) 9545 1311

Asian Regional Office
81G, Jalan SS 21/60
Damansara Utama
47400 Petaling Jaya
Malaysia
T: 60 (03) 7729 3873
F: 60 (03) 7727 4658

Securities Exchange Listing
The ordinary shares of Vita Life Sciences Limited are listed on the Australian Securities Exchange Ltd (code: VSC).

Auditor
Russell Bedford NSW
Level 42, Suncorp Place
259 George Street
Sydney NSW 2000

Banker
Westpac Banking Corporation

National Australia Bank Limited

Solicitor

Steven Kunstler

Share Registry
Gould Ralph Pty Ltd
Level 42, Suncorp Place
259 George Street
Sydney NSW 2000
T: 61 (02) 9032 3000
F: 61 (02) 9032 3088

Change of Address
Shareholders who have changed address should advise our share registry in writing.

Annual Report Mailing
Shareholders who do not want the annual report or who are receiving more than one copy should advise the share registry in writing.

Vita Life Website
Vita Life has a website containing information about the Company, its Business and Products.

www.vitalifesciences.com.au